casirivimab

GPTKB entity

Statements (76)
Predicate Object
gptkbp:instance_of gptkb:monoclonal_antibody
gptkbp:accessories logistical issues during distribution
gptkbp:administered_by intravenous infusion
gptkbp:administration_guidelines administered as soon as possible after diagnosis
gptkbp:approves gptkb:FDA
November 2020
gptkbp:availability available in multiple countries
gptkbp:business_model adhered to in trials
gptkbp:can_be_combined_with gptkb:imdevimab
gptkbp:class antiviral agent
gptkbp:clinical_trial gptkb:United_States
gptkb:Regeneron_Pharmaceuticals
Phase 3
randomized controlled trials
positive efficacy results
multiple phases conducted
open for eligible participants
gptkbp:clinical_trial_phase_results Phase 3 results published
gptkbp:clinical_use post-exposure prophylaxis
gptkbp:collaboration healthcare providers
gptkbp:collaborations with academic institutions
gptkbp:developed_by gptkb:Regeneron_Pharmaceuticals
gptkbp:distribution managed by federal agencies
allocated by government agencies
gptkbp:dosage_form solution for infusion
gptkbp:duration single administration
gptkbp:eligibility must meet specific criteria
gptkbp:feedback generally positive
gptkbp:financial_support available for eligible patients
gptkbp:funding funded by government grants
gptkbp:healthcare facilitated through healthcare systems
https://www.w3.org/2000/01/rdf-schema#label casirivimab
gptkbp:impact significant in COVID-19 management
gptkbp:indication mild to moderate COVID-19
gptkbp:interacts_with other monoclonal antibodies
gptkbp:invention gptkb:Regeneron_Pharmaceuticals
gptkbp:is_effective_against reduces hospitalization rates
gptkbp:is_monitored_by monitor for allergic reactions
recommended after administration
gptkbp:marketed_as gptkb:REGEN-COV
gptkbp:mechanism_of_action neutralizes the virus
gptkbp:part_of gptkb:REGEN-COV
gptkbp:patient_education informed about potential side effects
gptkbp:patient_population high-risk patients
gptkbp:pharmacokinetics binds to the spike protein
half-life of approximately 20 days
gptkbp:price varies by provider
gptkbp:provides_guidance_on outpatient
recommended for certain patients
updated regularly based on new data
gptkbp:publication published in medical journals
gptkbp:regulatory_compliance Emergency Use Authorization
based on clinical trial results
gptkbp:research_focus COVID-19 variants
COVID-19 treatment options
gptkbp:research_output reduction in viral load
gptkbp:route_of_administration subcutaneous injection
gptkbp:safety collected from clinical trials
gptkbp:safety_features generally well tolerated
gptkbp:safety_measures ongoing post-marketing surveillance
gptkbp:service_frequency single dose
gptkbp:side_effect infusion-related reactions
mandatory for healthcare providers
gptkbp:supply_availability limited supply during peak demand
gptkbp:supply_chain gptkb:monoclonal_antibody
gptkbp:supply_limitations due to high demand
gptkbp:targets SARS-Co V-2 virus
gptkbp:treatment improved recovery rates
established for administration.
shown in clinical studies
gptkbp:type_of_insurance covered by many insurance plans
gptkbp:used_for treatment of COVID-19
gptkbp:bfsParent gptkb:REGEN-COV
gptkb:Regen-Cov
gptkb:REGN-COV2
gptkbp:bfsLayer 5